6-MAPB
Chemical compound
From Wikipedia, the free encyclopedia
6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA.[1][2][3][4][5] It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT1B receptor agonist.[6] The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives.[citation needed] 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.[7][8] It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.[9]
- CA: Schedule I
- DE: NpSG (Industrial and scientific use only)
- UK: Class B
| Clinical data | |
|---|---|
| Other names | 1-(Benzofuran-6-yl)-N-methylpropan-2-amine |
| Routes of administration | Oral[1] |
| Drug class | Monoamine releasing agent; Serotonin 5-HT1B receptor agonist |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Duration of action | 6–8 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H15NO |
| Molar mass | 189.258 g·mol−1 |
| 3D model (JSmol) | |
| |
| |